Efficacy of Nebulized Versus Intravenous N- Acetylcysteine in Airway Clearance in Broncheictasis

NCT07293884 NA NOT_YET_RECRUITING

It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity. Additionally, the Spanish guidelines on the treatment of bronchiectasis indicate that the use of N-acetylcysteine should be considered for patients with bronchiectasis and COPD. Therefore, as a classic mucolytic agent with antioxidant and anti-inflammatory properties, N-acetylcysteine can be effective in the treatment of bronchiectasis

Details

Lead sponsor	Assiut University
Phase	NA
Status	NOT_YET_RECRUITING
Enrolment	70
Start date	2025-12
Completion	2026-04

Conditions

• Broncheictasis

Interventions

• N Acetyle cysteine given by IV injection
• Nebulized N Acetyle cysteine

Primary outcomes

• sputum viscosity score — At the end of 1 week of treatment
  Sputum viscosity score \\(0\\): Normal (liquid)\\(1\\): Mildly increased viscosity (fluid)\\(2\\): Moderately increased viscosity (viscous)\\(3\\): Severely increased viscosity (sticky)
• Amount of sputum — At the end of 1 week treatment
• Expectoration difficulty score — At the end of 1 week of treatment
  Expectoration difficulty score \\(0\\): No difficulty\\(1\\): Mild difficulty\\(2\\): Moderate difficulty\\(3\\): Marked difficulty